 OncLive | Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review OncLive So far, two mTOR inhibitors, temsirolimus and everolimus, have been approved and widely characterized for treatment of advanced RCC. These agents lead to G1 growth arrest after binding to a protein complex and inhibiting mTOR, and have been shown to ... |
